Drug Profile
Sodium selenate - Velacor Therapeutics
Alternative Names: VEL-015Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Velacor Therapeutics
- Class Antidementias; Trace elements
- Mechanism of Action Antioxidants; Protein phosphatase 2A stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Progressive supranuclear palsy
- No development reported Alzheimer's disease
Most Recent Events
- 20 Jul 2015 No recent reports on development identified - Phase-II for Alzheimer's disease (Early-stage disease) in Australia (PO)
- 19 Feb 2013 Velacore Therapeutics initiates enrolment in a phase II trial for Alzheimer's disease (early-stage disease) in Australia (ACTRN12613000170729)
- 16 Nov 2011 Phase-II clinical trials in Alzheimer's disease (early-stage disease) in Australia (PO)